ArticleWiener klinische Wochenschrift2026
Treatment of complex perianal fistulas with fistula laser closure : Application of the IDEAL 2A framework.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimFistula laser closure (FiLaC) is a minimally invasive treatment option for perianal fistulas with acceptable healing rates. We report implementation and include short-term results in line with the IDEAL (Idea, Development, Exploration, Assessment, Long-term study) 2A framework in patients with complex fistulas and previous surgical repair attempts.
methodProspective audit data from 56 consecutive patients with perianal fistulas treated between June 2024 and January 2025. The FiLaC procedure included cleaning the fistula tract, application of approximately 100 J/cm fistula length and closing of the internal opening with a stitch. All patients refused more invasive operations and/or were not suitable for advanced repair.
resultsPatients were diagnosed with fistulas after a median of 34.5 months (interquartile range, IQR 13.8-54.2 months), with a median of 3 months (IQR 1.8-4.0 months) following previous fistula-related surgery. Most patients had cryptoglandular fistulas (80.4%) while 19.6% had inflammatory bowel disease-related fistulas. Most fistulas were transsphincteric (69.6%), and only 32.1% of patients were seton-free before the procedure. During the first postprocedural outpatient visit at 7.9 weeks (median; IQR 6.4-10.9 weeks), clinical healing was evident in 14 (24.1%) cases, and 23 (39.7%) patients reported relevant symptomatic improvement. A total of 21 patients (36.2%) did not report any improvement, 3 patients (5.2%) experienced a postoperative complication, with 1 (1.7%) requiring a return to theatre due to an abscess. After a median of 10.4 months, the "seton-free rate" was 67.9%, This represents a relevant improvement to 32.1% before FiLaC.
conclusionThe use of FiLaC is a safe, sphincter-preserving treatment for complex perianal fistulas and was associated with a marked increase in the seton-free rate. While complete fistula healing rates were lower than previously reported, FiLaC remains an option for patients with complex disease.
Indexed as
Identifiers
42593507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.